Vanguard Capital Management’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$163M Buy
9,011,920
+47,497
+0.5% +$910K ﹤0.01% 1235
2026
Q2
$168M Buy
8,964,423
+1,576,958
+21% +$22.9M ﹤0.01% 1253
2026
Q1
$73.5M Buy
+7,387,465
New +$66.1M ﹤0.01% 1640

Other funds holding RLAY

Vanguard Capital Management's RLAY Position: Q3 2026 in Review

Vanguard Capital Management increased its Relay Therapeutics (RLAY) stake by 0.53% in Q3 2026, buying an estimated $910K and bringing the position to 9,011,920 shares worth $163M. The position accounts for ﹤0.01% of the portfolio, ranked #1235.

Vanguard Capital Management first reported a position in RLAY in Q1 2026 and has held it in 3 quarters since. The position peaked at $168M in Q2 2026. 261 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

  • Vanguard Capital Management held 9,011,920 shares of Relay Therapeutics worth $163M as of Q3 2026.
  • Vanguard Capital Management bought 47,497 Relay Therapeutics shares in Q3 2026, an estimated $910K.
  • Relay Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1235 holding.
  • Vanguard Capital Management first reported a position in Relay Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Relay Therapeutics position peaked at $168M in Q2 2026.
  • 261 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.